1. Home
  2. CRI vs NTLA Comparison

CRI vs NTLA Comparison

Compare CRI & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Carter's Inc.

CRI

Carter's Inc.

HOLD

Current Price

$31.77

Market Cap

1.2B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.61

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRI
NTLA
Founded
1865
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
986.9M
IPO Year
2003
2016

Fundamental Metrics

Financial Performance
Metric
CRI
NTLA
Price
$31.77
$9.61
Analyst Decision
Sell
Buy
Analyst Count
5
22
Target Price
$28.80
$19.83
AVG Volume (30 Days)
1.1M
4.0M
Earning Date
10-27-2025
11-06-2025
Dividend Yield
3.13%
N/A
EPS Growth
N/A
N/A
EPS
2.45
N/A
Revenue
$2,832,687,000.00
$57,528,000.00
Revenue This Year
$1.58
$1.96
Revenue Next Year
$0.14
N/A
P/E Ratio
$13.03
N/A
Revenue Growth
N/A
33.52
52 Week Low
$23.38
$5.90
52 Week High
$56.89
$28.25

Technical Indicators

Market Signals
Indicator
CRI
NTLA
Relative Strength Index (RSI) 48.97 47.53
Support Level $31.80 $8.74
Resistance Level $33.38 $9.55
Average True Range (ATR) 1.25 0.57
MACD -0.06 0.31
Stochastic Oscillator 18.73 83.79

Price Performance

Historical Comparison
CRI
NTLA

About CRI Carter's Inc.

Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: